Health · 2 views
Valbenazine for Tardive Dyskinesia Tied to Less Antipsychotic Drop-Off
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 2 Community interest
Brief read Under 1 min brief 30 words
Summary
(MedPage Today) -- Starting valbenazine (Ingrezza) to treat tardive dyskinesia might reduce antipsychotic discontinuation in patients newly diagnosed with the side effect, a retrospective cohort study of Medicare claims indicated.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Researchers identify blood-based biomarkers that could help personalize treatment for autoimmune diabetesContinue reading
- Q&A: Researcher investigates pharmacological approaches to breast cancer preventionContinue reading
- Trial Stopped Early for Superiority of LBBP-Tuned PacemakersContinue reading
- Yoga-based cardiac rehab improved quality of life in people living with heart failureContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow